Home/Pipeline/Anti-infectives Program

Anti-infectives Program

Undisclosed Bacterial Infection

PreclinicalActive

Key Facts

Indication
Undisclosed Bacterial Infection
Phase
Preclinical
Status
Active
Company

About PeptiDream

PeptiDream's mission is to revolutionize drug discovery by developing macrocyclic peptides as a new therapeutic modality to address undruggable targets. The company has achieved remarkable success through its proprietary PDPS technology, securing high-value partnerships with nearly every major global pharmaceutical firm. Its strategy combines a capital-efficient platform business with the advancement of a proprietary pipeline, particularly in oncology and infectious diseases. This dual approach has generated significant revenue and driven its valuation to over $150 billion, positioning it as a dominant force in the peptide therapeutics space.

View full company profile